If the initial results come back negative, clinicians have the option to receive subsequent analysis by re-requisition to the broader Invitae Frontotemporal Dementia Panel, which analyzes up to 13 genes associated with frontotemporal dementia (FTD).
This subsequent analysis is offered at no additional charge if ordered within 90 days of the original report release. No new sample is required.
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website.
Alector, the Sponsor of this FTD genetic screening, is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing and investigating a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s investigational products are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer's Disease.
Greaves and Rohrer Journal of Neurology (2019) 266:2075–2086.
Gass et al. Hum Mol Genet. 2006 Oct 15;15(20):2988-3001.
Gossye Front Neurosci. 2019; 13: 757.
Takada Dement Neuropsychol 2015 September;9(3):219-229.